LENALIDOMIDE
| Brand name | LENALIDOMIDE |
|---|---|
| Active ingredient | LENALIDOMIDE |
| Strength | 5MG |
| Dosage form | CAPSULE |
| Route | ORAL |
| Modality | Small molecule |
| FDA approval | March 2023 |
| Marketing status | RX |
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.